Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R. Fabbiani M, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397552 Free PMC article.
Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients.
Torti C, Quiros-Roldan E, Tirelli V, Regazzi-Bonora M, Moretti F, Pierotti P, Orani A, Maggi P, Cargnel A, Patroni A, De Luca A, Carosi G; RADAR Study Group of the Master Cohort. Torti C, et al. AIDS Patient Care STDS. 2004 Nov;18(11):629-34. doi: 10.1089/apc.2004.18.629. AIDS Patient Care STDS. 2004. PMID: 15633260 Clinical Trial.
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. Torti C, et al. Clin Infect Dis. 2005 Jun 15;40(12):1828-36. doi: 10.1086/429917. Epub 2005 May 12. Clin Infect Dis. 2005. PMID: 15909273 Clinical Trial.
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G. Torti C, et al. J Clin Virol. 2006 Apr;35(4):414-9. doi: 10.1016/j.jcv.2005.10.001. Epub 2005 Nov 8. J Clin Virol. 2006. PMID: 16280255 Clinical Trial.
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.
Quiros-Roldan E, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, Cusato M, Pierotti P, Tirelli V, Uccelli MC, Di Giambenedetto S, Castelnuovo F, Gargiulo F, Manca N, Carosi G; RADAR-Master Study Group. Quiros-Roldan E, et al. AIDS Patient Care STDS. 2007 Feb;21(2):92-9. doi: 10.1089/apc.2005.0037. AIDS Patient Care STDS. 2007. PMID: 17328658 Clinical Trial.
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).
Carosi G, Quiros-Roldan E, Torti C, Antinori A, Bevilacqua M, Bonadonna RC, Bonfanti P, Castagna A, Cauda R, d'Arminio-Monforte A, Di Gregorio P, Di Perri G, Esposito R, Fatuzzo F, Gervasoni C, Giannattasio C, Guaraldi G, Lazzarin A, Lo Caputo S, Maggi P, Mazzotta F, Moroni M, Prestileo T, Ranieri R, Rizzardini G, Russo R, Galli M; Members of the Italian Cardiovascular Risk Guidelines Working Group. Carosi G, et al. Infection. 2007 Jun;35(3):134-42. doi: 10.1007/s15010-007-6295-5. Infection. 2007. PMID: 17565453
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort. Di Giambenedetto S, et al. Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7. Infection. 2009. PMID: 19669091
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Torti C, et al. BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23. BMC Infect Dis. 2011. PMID: 21266068 Free PMC article. Clinical Trial.
310 results